Editorials

Tocilizumab for giant cell arteritis: what is optimal?

M. Kaymakci¹, K.J. Warrington²

Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. warrington.kenneth@mayo.edu

CER16689
2023 Vol.41, N°4
PI 0777, PF 0779
Editorials

Free to view
(click on article PDF icon to read the article)

PMID: 36995336 [PubMed]

Received: 19/03/2023
Accepted : 21/03/2023
In Press: 27/03/2023
Published: 18/04/2023